NCT07496736进行中（未招募）3 期
Post-Exposure Influenza Chemoprophylaxis With Oseltamivir for Five Days vs Ten Days in Acute-Care Hospital: a Non-Inferiority Randomized Open-Label Study
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 进行中（未招募）
- 入组人数
- 200
- 试验地点
- 1
- 主要终点
- frequency of influenza
研究概览
简要总结
The purpose of this study is to compare the efficacy of 5-day versus 10-day oseltamivir prophylactic treatment in patients who had been exposed to influenza in a hospital setting.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Prevention
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •18 years or older
- •exposure to influenza during hospitalization
- •risk factors for influenza complications
- •consent for participation obtained
排除标准
- •younger than 18 years
- •hematological malignancy
- •hospitalized in intensive care unit
- •refusal to participate
研究组 & 干预措施
oseltamivir 10 days
Active Comparator
post-exposure influenza prophylaxis with oseltamivir for 10 days
干预措施: Oseltamivir (Drug)
oseltamivir 5 days
Active Comparator
post-exposure influenza prophylaxis with oseltamivir for 5 days
干预措施: Oseltamivir (Drug)
结局指标
主要结局
frequency of influenza
时间窗: 10 days after completing prophylaxis
次要结局
未报告次要终点
研究者
Daša Stupica
MD, PhD, assoc prof
University Medical Centre Ljubljana
研究点 (1)
Loading locations...
相似试验
招募中
2 期
Phase 2b, multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy, immunogenicity and safety of one dose of OVX836 influenza vaccine 480μg, after intramuscular administration in healthy subjects aged 18-59 years2024-520354-37-00Osivax2,850
招募中
2 期
Feasibility and efficacy of concentrated ERP in patients with OCDCTRI/2025/09/094217University Grants Commission26
已完成
3 期
Immunogenicity and Safety Assessment of Rabies Vaccine (Vero Cell) for Human Use, Freeze-driedNCT07357545Sinovac Biotech Co., Ltd2,040
尚未招募
不适用
Effect of Oral Supplement on Influenza Vaccine Long-term ResponseNCT07357467Tsinghua University30
尚未招募
不适用
A study to find out if giving levofloxacin prevents infections in children and teenagers (1 to 18 years) receiving treatment for blood cancers (leukemia and lymphoma)CTRI/2025/09/095414AIIMS Bhopal102